Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period

International Journal of Infectious Diseases

Volumn 16, Issue 2, 2012, Pages

  Luo, Zhuanbo ^a   Li, Lanjuan ^a   Ruan, Bing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

China; Epidemiology; Hepatitis B vaccine; Hepatitis B virus

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

AMINO ACID SUBSTITUTION; ANTIBODY TITER; ANTIVIRAL THERAPY; CANCER MORTALITY; CANCER PREVENTION; CHINA; DISEASE CARRIER; DISEASE TRANSMISSION; DNA VIRUS; DRUG TREATMENT FAILURE; FOLLOW UP; GENE MUTATION; GESTATIONAL AGE; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH STATUS; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; INFECTION SENSITIVITY; LIVER CANCER; LIVER CELL CARCINOMA; PUBLIC HEALTH PROBLEM; REVIEW; RISK REDUCTION; SCREENING TEST; VACCINATION; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD;

CHINA; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; VACCINATION;

EID: 84862957325     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.10.009     Document Type: Review

References (71)

1. Cha C., Dematteo R.P. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005, 19:25-37.
2. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
3. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
4. Lok A.S. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004, 127:S303-S309.
5. Wang J.S., Huang T., Su J., Liang F., Wei Z., Liang Y., et al. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2001, 10:143-146.
6. Shi J., Zhu L., Liu S., Xie W.F. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005, 92:607-612.
7. Chen J.G., Zhang S.W., Chen W.Q. Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004-2005. Chin J Prev Med 2010, 44:383-389.
8. Bosch F.X., Ribes J. The epidemiology of primary liver cancer: global epidemiology. Viruses and liver cancer 2002, 1-16. Elsevier, Amsterdam, the Netherlands. E. Tabor (Ed.).
9. Luo R.H., Zhao Z.X., Zhou X.Y., Gao Z.L., Yao J.L. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol 2005, 11:4431-4434.
10. Xin Y.N., Xuan S.Y. Hepatitis B virus, hepatitis C virus infection and primary liver cancer research. Chin J Clin Hepatol 2006, 22:64-65.
11. Nguyen V.T., Law M.G., Dore G.J. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009, 16:453-463.
12. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005, 34(Suppl 1):S1-S3.
13. Global Advisory Group. Weekly Epidemiol Rec 1992, 67:11-16. World Health Organization: Expanded Programme on Immunization.
14. World Health Organization. Global immunization 1989-2010, 3rd dose of hepatitis B coverage in infants. Geneva: WHO; 2010. Available at: (accessed November 2011). http://www.who.int/immunization_monitoring/diseases/HepB_coverage.jpg.
15. World Health Organization Vaccines and Biologicals. WHO vaccine preventable disease monitoring system: 2009 global summary (data up to 2008). Geneva: WHO; 2009. Available at: (accessed July 27, 2011). http://whqlibdoc.who.int/hq/2009/WHO_IVB_2009_eng.pdf.
16. Chen D.S. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009, 50:805-816.
17. Zhuang H. Hepatitis B vaccination in China. Basic Med Sci Clin 2004, 24:136-140.
18. The guideline of prevention and treatment for chronic hepatitis B. Chin J Hepatol 2005, 13:881-891. Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association.
19. Progress in hepatitis B prevention through universal infant vaccination-China, 1997-2006. MMWR Morb Mortal Wkly Rep 2007, 56:441-445. Centers for Disease Control and Prevention (CDC).
20. Yao J., Yang J.Z., Mo S.H., Zhang Z., Mo S.T., Mei L.L., et al. Investigation on immunization coverage rate and immune effect of hepatitis B vaccine among newborns in Zhejiang Province. Chin J Vaccines Immunization 2000, 6:132-135.
21. Liu P.B., Xu H.W. Certain question discussion of hepatitis B vaccine inoculation. China Public Health 2000, 16:73-74.
22. Xia G.L., Liu C.B., Cao H.L., Bi S.L., Zhan M.Y., Su C.A., et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Comm 1996, 5:62-73.
23. Liang X.F., Chen Y.S., Wang X.J., He X., Chen L.J., Wang J., et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3 years old. Chin J Epidemiol 2005, 26:655-658.
24. Zhou Y.X. Public place jobholders hepatitis B virus infection and vaccine inoculation investigation. Modern Prev Med 2005, 32:1683-1684.
25. Tian C., Ma J.C., Han C.Z., Qi S.X., Hao Z.Y., Chen J.C., et al. Infective status of HBV among population after 19 years immunization vaccine. Chin J Vaccines Immunization 2007, 13:4-7.
26. Wu W.S., Sun C.M., Jiang M.B., Zhang G.H., Shen F.J., Liu C.B., et al. Serological study on status of hepatitis B virus infection and carry in vaccinated population: a historical comparison. Chin J Vaccines Immunization 2005, 11:276-278.
27. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
28. Dai Z.C., Qi G.M. Epidemiological investigation of viral hepatitis in China 1996, Beijing Science and Technology Literature Press, Beijing.
29. Luo Y.X., Li J.J., Deng F., Li H., Zhang J.K., Cai H.G., et al. The analysis of serological immune effect after HB vaccine being brought into the expanded program on immunization for ten years in Guangdong province. Chin J Vaccines Immunization 2003, 9:293-296.
30. Ma J.C., Liu H.B., Zhang Y.L., Meng Z.D., Han C.Q., Xing Z.C., et al. A 14-year survey for hepatitis B vaccine immune efficacy in newborns in rural area after universal immunization. Chin J Vaccines Immunization 2002, 8:181-184.
31. Lei R.Y., Luo Y.X., Xie X., Li H., Shao X.P., Lin Y.J., et al. Serological epidemiology of HBsAg and Anti-HBs for children in Zhujiang delta area of Guangdong Province. Chin J Vaccines Immunization 2006, 12:112-114.
32. Yu B., Wang X., Han R.H., Chen Z.C., Chen Z.F. Studies and analysis on immunization coverage rate of hepatitis B (HB) vaccine and the HBsAg carrier rate of children below 3 years old and incidence rate for the past ten years in Wuhan city. Chin J Vaccines Immunization 2005, 11:117-119.
33. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009, 200:39-47.
34. Yao G.B. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996, 38(Suppl 2):S39-S42.
35. Chen Y.S., Wang X.J., Liang X.F., He X., Wang J., Chen L.J., et al. Seroepidemiological study on viral hepatitis B of the eastern, middle, and western areas in China. Chin J Vaccines Immunization 2006, 12:246-249.
36. Shen L.P., Zhang Y., Wang F., Zhang S., Yang J.Y., Fang K.X., et al. Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme. Epidemiol Infect 2011, 139:1159-1165.
37. Blumberg B.S. Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci U S A 1997, 94:7121-7125.
38. A WHO meeting. Bull World Health Organ 1983, 61:731-744. World Health Organization. Prevention of hepatocellular carcinoma by immunization.
39. Lee M.S., Kim D.H., Kim H., Lee H.S., Kim C.Y., Park T.S., et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol 1998, 27:316-319.
40. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855-1859.
41. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
42. Stevens C.E., Beasley R.P., Tsui J., Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
43. Beasley R.P., Hwang L.Y., Lee G.C., Lan C.C., Roan C.H., Huang F.Y., et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2:1099-1102.
44. Lin H.H., Chang M.H., Chen D.S., Sung J.L., Hong K.H., Young Y.C., et al. Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysis of prophylaxis failure. Vaccine 1991, 9:457-460.
45. Ngui S.L., Andrews N.J., Underhill G.S., Heptonstall J., Teo C.G. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998, 27:100-106.
46. Lee S.D., Lo K.J., Wu J.C., Tsai Y.T., Wang J.Y., Ting L.P., et al. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986, 6:369-373.
47. Ip H.M., Lelie P.N., Wong V.C., Kuhns M.C., Reesink H.W. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989, 1:406-410.
48. Burk R.D., Hwang L.Y., Ho G.Y., Shafritz D.A., Beasley R.P. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994, 170:1418-1423.
49. del Canho R., Grosheide P.M., Schalm S.W., de Vries R.R., Heijtink R.A. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol 1994, 20:483-486.
50. Liu S.L., Dong Y., Zhang L., Li M.W., Wo J.E., Lu L.W., et al. Influence of HBV gene heterogeneity on the failure of immunization with HBV vaccines in eastern China. Arch Virol 2009, 154:437-443.
51. Deng X.Q., Xu Z.Y., Ouyang P.Y., Lu P.H., Zhu Q.R., Zhuang Y.L. Relationship between maternal HBsAg, HBeAg titers and hepatitis B vaccine failure in infants born to HBV carrier mothers. Chin J Infect Dis 2000, 18:232-235.
52. Wang Z., Zhang J., Yang H., Li X., Wen S., Guo Y., et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003, 71:360-366.
53. Song Y.M., Sung J., Yang S., Choe Y.H., Chang Y.S., Park W.S. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007, 166:813-818.
54. Kang J.H., Moon J.W., Kong S.H., Hwang K.S., Mok J.S., Lee H.J. Comparison of the seroconversion rate after primary hepatitis B vaccination and after revaccination of non-responders in full-term infants according to mother's HBsAg seropositivity. Korean J Pediatr 2008, 51:1165-1171.
55. Carman W.F., Zanetti A.R., Karayiannis P., Waters J., Manzillo G., Tanzi E., et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336:325-329.
56. Hsu H.Y., Chang M.H., Ni Y.H., Lin H.H., Wang S.M., Chen D.S. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997, 26:786-791.
57. Francois G., Kew M., Van Damme P., Mphahlele M.J., Meheus A. Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?. Vaccine 2001, 19:3799-3815.
58. Hu Q., Huang J.G., Lei Y.C., Huang H.P., Yang Y., Yang D.L. Detection of mutants of the 'a' determinant region of hepatitis B surface antigen S gene among Wuhan childhood patients. Chin J Hepatol 2005, 13:594-596.
59. Wang C.M., Han G.R., Wang G.J. The relationship between hepatitis B virus S gene variation, genetype and immunoprophylaxis failure to intrauterine infection of hepatitis B virus. Chin J Infect Dis 2009, 27:114-117.
60. Oon C.J., Lim G.K., Ye Z., Goh K.T., Tan K.L., Yo S.L., et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995, 13:699-702.
61. Ngui S.L., O'Connell S., Eglin R.P., Heptonstall J., Teo C.G. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 1997, 176:1360-1365.
62. Nainan O.V., Khristova M.L., Byun K., Xia G., Taylor P.E., Stevens C.E., et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002, 68:319-327.
63. Kim J.H., Koh D.K., Hur J.K., Kang J.H., Nainan O.V., Margolis H.S. The incidence rate of hepatitis B virus surface gene variants in Korean children with immunoprophylaxis failure of perinatal infection. Korean J Hepatol 2005, 11:320-328.
64. Ogata N., Cote P.J., Zanetti A.R., Miller R.H., Shapiro M., Gerin J., et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999, 30:779-786.
65. Cui F.Q., Pur H.T., Liang X.F. Analysis on new born hepatitis B immunization coverage and pregnant women hospital delivery rate in different region. Chin J Vaccines Immunization 2007, 13:1-3.
66. Kao J.H., Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403.
67. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45:1056-1075.
68. Margolis H.S. Hepatitis B virus infection. Bull World Health Organ 1998, 76(Suppl 2):152-153.
69. Xu Q., Xiao L., Lu X.B., Zhang Y.X., Cai X. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 2006, 12:3434-3437.
70. Li S.X., Guo Y.Z., Zhang M.L. The clinical observation of pregnant to inject HBIG in the later period and the newborn to inject HBIG and HB vaccine blocking the HBV maternal infant transmission. Maternal and Child Health Care of China 2008, 23:2611-2612.
71. Kabir A., Alavian S.M., Ahanchi N., Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res 2006, 36:265-271.